Orion and Bayer expand clinical development program for darolutamide in prostate cancer
ORION CORPORATION PRESS RELEASE 23 March 2023 at 15:00 EET Orion and Bayer expand clinical development…
Year: 2023
Orion and Bayer expand clinical development program for darolutamide in prostate cancer
ORION CORPORATION PRESS RELEASE 23 March 2023 at 15:00 EET Orion and Bayer expand clinical development…
Novan to Report Full Year 2022 Financial Results on March 30, 2023
DURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:…
Novan to Report Full Year 2022 Financial Results on March 30, 2023
DURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:…
Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
Sirona Biochem Announces Debenture Financing
VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) — Sirona Biochem Corp. (TSX-V: SBM) (FSE:…
Sirona Biochem Announces Debenture Financing
VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) — Sirona Biochem Corp. (TSX-V: SBM) (FSE:…
T2 Biosystems Affirms Plans to Add Candida Auris Detection to the FDA-Cleared T2Candida Panel
LEXINGTON, Mass., March 23, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
T2 Biosystems Affirms Plans to Add Candida Auris Detection to the FDA-Cleared T2Candida Panel
LEXINGTON, Mass., March 23, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
Outpace Bio, a Leader in Protein Design & Cell Engineering, Adds Bahija Jallal to Board of Directors
Jallal, an internationally recognized biopharma leader, oversaw historic approval of the world’s first TCR therapy…
Outpace Bio, a Leader in Protein Design & Cell Engineering, Adds Bahija Jallal to Board of Directors
Jallal, an internationally recognized biopharma leader, oversaw historic approval of the world’s first TCR therapy…
Lucy Scientific Discovery Announces Partnership with High Times® to Develop and Distribute a New Line of Psychoactive Products
‘Mindful by Lucy’ Mushroom Microdose Supplements VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) —…
Lucy Scientific Discovery Announces Partnership with High Times® to Develop and Distribute a New Line of Psychoactive Products
‘Mindful by Lucy’ Mushroom Microdose Supplements VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) —…
IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023
LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development…
IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023
LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development…
Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., March 23, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., March 23, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential
LOS ANGELES, March 23, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”)…
Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential
LOS ANGELES, March 23, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”)…